PDCD1 and hepatocellular carcinoma: In a randomized phase III clinical study, 543 patients with HCC were administered 200 mg of camrelizumab (anti-PD-1) on day 1 after 14 days in addition to 250 mg of rivoceranib (TKI) one time a day or 400 mg of sorafenib two times a day.